PL360060A1 - Antithrombotic agents - Google Patents

Antithrombotic agents

Info

Publication number
PL360060A1
PL360060A1 PL36006000A PL36006000A PL360060A1 PL 360060 A1 PL360060 A1 PL 360060A1 PL 36006000 A PL36006000 A PL 36006000A PL 36006000 A PL36006000 A PL 36006000A PL 360060 A1 PL360060 A1 PL 360060A1
Authority
PL
Poland
Prior art keywords
antithrombotic agents
fixabs
suk
streptokinase
urokinase
Prior art date
Application number
PL36006000A
Other languages
English (en)
Polish (pl)
Inventor
Frank C. Barone
Michael N. Blackburn
Giora Z. Feuerstein
John R. Toomey
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of PL360060A1 publication Critical patent/PL360060A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PL36006000A 2000-05-15 2000-10-05 Antithrombotic agents PL360060A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15

Publications (1)

Publication Number Publication Date
PL360060A1 true PL360060A1 (en) 2004-09-06

Family

ID=24283688

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36006000A PL360060A1 (en) 2000-05-15 2000-10-05 Antithrombotic agents

Country Status (20)

Country Link
US (1) US20050037006A1 (enExample)
EP (2) EP1825864A3 (enExample)
JP (1) JP2004516236A (enExample)
KR (2) KR20070116192A (enExample)
CN (2) CN101134107A (enExample)
AT (1) ATE345816T1 (enExample)
AU (2) AU7858400A (enExample)
BR (1) BR0015872A (enExample)
CA (1) CA2411369A1 (enExample)
CZ (1) CZ20023778A3 (enExample)
DE (1) DE60032029T2 (enExample)
ES (1) ES2277597T3 (enExample)
HU (1) HU225874B1 (enExample)
IL (1) IL152831A0 (enExample)
MX (1) MXPA02011385A (enExample)
NO (1) NO20025463L (enExample)
NZ (1) NZ522632A (enExample)
PL (1) PL360060A1 (enExample)
WO (1) WO2001087339A1 (enExample)
ZA (1) ZA200209265B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
PT2438913T (pt) 2002-03-20 2020-05-27 Us Veterans Affairs Canal de catiões não seletivos em células neurais e compostos que bloqueiam o canal para utilização no tratamento de edema cerebral
US7872048B2 (en) 2004-09-18 2011-01-18 University Of Maryland, Baltimore Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel
EP2359832A3 (en) 2004-09-18 2011-11-23 University of Maryland, Baltimore Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
EP3103451A1 (en) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targetting ncca-atp channel for organ protection following ischemic episode
CA2974689C (en) 2007-06-22 2020-02-25 The United States Of America As Represented By The Department Of Veters Affairs Inhibitors of ncca-atp channels for therapy
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
AU2008326348B2 (en) * 2007-11-21 2014-01-30 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
WO2018199214A1 (ja) 2017-04-27 2018-11-01 中外製薬株式会社 薬物動態が改善された血液凝固第ｉｘ因子
US20240018503A1 (en) * 2017-04-27 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
AU766551C (en) * 1998-08-28 2005-02-17 Genentech Inc. Human anti-factor IX/IXa antibodies

Also Published As

Publication number Publication date
BR0015872A (pt) 2004-08-03
NO20025463D0 (no) 2002-11-14
EP1282444A4 (en) 2004-06-30
DE60032029D1 (de) 2007-01-04
DE60032029T2 (de) 2007-05-31
CN1501812A (zh) 2004-06-02
EP1282444B1 (en) 2006-11-22
EP1282444A1 (en) 2003-02-12
AU7858400A (en) 2001-11-26
JP2004516236A (ja) 2004-06-03
HUP0301804A2 (hu) 2003-08-28
US20050037006A1 (en) 2005-02-17
WO2001087339A1 (en) 2001-11-22
IL152831A0 (en) 2003-06-24
CZ20023778A3 (cs) 2003-08-13
EP1825864A3 (en) 2007-09-12
MXPA02011385A (es) 2004-01-26
CN100339132C (zh) 2007-09-26
NZ522632A (en) 2005-05-27
KR20070116192A (ko) 2007-12-06
CN101134107A (zh) 2008-03-05
ATE345816T1 (de) 2006-12-15
HU225874B1 (en) 2007-11-28
NO20025463L (no) 2003-01-09
KR20030034071A (ko) 2003-05-01
ZA200209265B (en) 2003-10-22
AU2000278584B2 (en) 2006-11-16
ES2277597T3 (es) 2007-07-16
HUP0301804A3 (en) 2005-12-28
CA2411369A1 (en) 2001-11-22
EP1825864A2 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
IL152831A0 (en) Antithrombotic agents
DE60042214D1 (enExample)
AU6379101A (en) Highly selective inhibitors of the urokinase plasminogen activator
WO2003057831A3 (en) Dtat fusion toxin
EP0692968A4 (en) UROKINASE PLASMINOGEN ACTIVATOR FRAGMENTS
DK0669394T3 (da) Bifunktionelle urokinasevarianter med forbedrede fibrinolytiske egenskaber og thrombinhæmmende virkninger
ZA887556B (en) Modified tissue plasminogen activator
DE59001558D1 (de) Thrombolytisch wirkendes kombinationspraeparat.
AU2002320150A1 (en) Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent
MXPA02001936A (es) Tratamiento mixto con una variante de activador de plasminogeno tisular y heparina de peso molecular bajo.

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)